Atorvastatin calcium nursing implications
Pro Research Analysisby 
Searched over 200M research papers
Nursing Implications of Atorvastatin Calcium
Cardiovascular Protection in Chronic Kidney Disease Patients
Cluster Nursing and Atorvastatin Calcium
In patients with end-stage chronic kidney disease undergoing peritoneal dialysis, the combination of cluster nursing and atorvastatin calcium has shown significant cardiovascular protective effects. Research indicates that the incidence of cardiovascular disease in patients receiving this combined treatment was significantly lower (13.34%) compared to those who did not (36.67%) . This suggests that atorvastatin calcium, when used alongside intensive nursing care, can effectively reduce cardiovascular risks in these patients.
Quality of Life and Hospitalization
The same study also found that patients in the observation group had a shorter hospital stay and improved quality of life across various dimensions, including material life, social function, psychological function, and physical function, compared to the control group . This highlights the importance of integrating atorvastatin calcium with comprehensive nursing care to enhance patient outcomes and reduce healthcare costs.
Treatment of Asymptomatic Adults with Elevated Coronary Calcium Scores
Lipid-Lowering and Antioxidant Therapy
A randomized clinical trial investigated the effects of atorvastatin, vitamin C, and vitamin E on asymptomatic adults with elevated coronary calcium scores. The study found that while atorvastatin significantly reduced total cholesterol, low-density lipoprotein cholesterol, and triglycerides, it did not affect the progression of coronary calcification . This suggests that while atorvastatin is effective in lipid management, its impact on coronary calcification progression may be limited.
Potential Reduction in ASCVD Events
Although the primary endpoint of reducing atherosclerotic cardiovascular disease (ASCVD) events was not significantly achieved, there was an indication that atorvastatin might reduce ASCVD events in participants with higher baseline calcium scores (>400) . This points to a potential benefit of atorvastatin in specific subgroups of patients, warranting further investigation.
Conclusion
Atorvastatin calcium, particularly when combined with intensive nursing care, offers significant cardiovascular protection and quality of life improvements for patients with end-stage chronic kidney disease undergoing peritoneal dialysis. However, its role in preventing coronary calcification progression in asymptomatic adults with elevated coronary calcium scores remains inconclusive, though it may reduce ASCVD events in certain high-risk groups. These findings underscore the importance of personalized patient care and the potential benefits of integrating atorvastatin calcium into comprehensive treatment plans.
Sources and full results
Most relevant research papers on this topic
Cardiovascular Protective Effect of Intensive Nursing Combined with Atorvastatin Calcium in Patients with End-stage Chronic Kidney Disease undergoing Peritoneal Dialysis
Cluster nursing combined with atorvastatin calcium can shorten hospital stays, reduce costs, and improve quality of life for patients undergoing peritoneal dialysis.
Atorvastatin induced hepatic oxidative stress and apoptotic damage via MAPKs, mitochondria, calpain and caspase12 dependent pathways.
Atorvastatin induces hepatic oxidative stress and apoptosis in mice through MAPKs, mitochondria, and ER dependent pathways, with calcium ions and reactive oxygen species acting as key mediators of apoptosis.
DOI
Optimization of transdermal atorvastatin calcium - loaded proniosomes: Restoring lipid profile and alleviating hepatotoxicity in Poloxamer 407-induced hyperlipidemia.
Optimized transdermal atorvastatin calcium-loaded proniosomal gel effectively restores lipid profile and reduces statin-induced hepatotoxicity in hyperlipidemia without causing liver damage.
A Novel Sustained Anti-Inflammatory Effect of Atorvastatin—Calcium PLGA Nanoparticles: In Vitro Optimization and In Vivo Evaluation
Atorvastatin-Calcium PLGA nanoparticles effectively sustain anti-inflammatory effects for approximately three days, restoring healthy epidermal/dermal architecture.
Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.
Amorphous atorvastatin calcium nanoparticles prepared using the supercritical antisolvent process show improved solubility, faster dissolution rate, and increased absorption compared to unprocessed drug.
DOI